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TurkeyAbstractWe aimed to describe clinical, laboratory, diagnostic and therapeutic features of spinal tuberculosis (ST), also known as Pott disease. A total of
314 patients with ST from 35 centres in Turkey, Egypt, Albania and Greece were included. Median duration from initial symptoms to the time
of diagnosis was 78 days. The most common complications presented before diagnosis were abscesses (69%), neurologic deﬁcits (40%), spinal
instability (21%) and spinal deformity (16%). Lumbar (56%), thoracic (49%) and thoracolumbar (13%) vertebrae were the most commonly
involved sites of infection. Although 51% of the patients had multiple levels of vertebral involvement, 8% had noncontiguous involvement
of multiple vertebral bodies. The causative agent was identiﬁed in 41% of cases. Histopathologic examination was performed in 200
patients (64%), and 74% were consistent with tuberculosis. Medical treatment alone was implemented in 103 patients (33%), while 211
patients (67%) underwent diagnostic and/or therapeutic surgical intervention. Ten percent of the patients required more than oneClin Microbiol Infect 2015; 21: 1008.e9–1008.e18
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CMI Batirel et al. Course of spinal tuberculosis 1008.e10surgical intervention. Mortality occurred in 7 patients (2%), and 77 (25%) developed sequelae. The distribution of the posttreatment sequelae
were as follows: 11% kyphosis, 6% Gibbus deformity, 5% scoliosis, 5% paraparesis, 5% paraplegia and 4% loss of sensation. Older age,
presence of neurologic deﬁcit and spinal deformity were predictors of unfavourable outcome. ST results in signiﬁcant morbidity as a
result of its insidious course and delayed diagnosis because of diagnostic and therapeutic challenges. ST should be considered in the
differential diagnosis of patients with vertebral osteomyelitis, especially in tuberculosis-endemic regions. Early establishment of deﬁnitive
aetiologic diagnosis and appropriate treatment are of paramount importance to prevent development of sequelae.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: hakanerdem1969@yahoo.comIntroductionTuberculosis (TB) is a global health problem infecting one-third
of the world’s population. It is a widespread disease, with 8.7
million new cases annually, and worldwide rates of TB have
increased in parallel with AIDS incidence [1]. In addition, TB
ranks second, just after HIV infection, among infectious causes
of mortality. Turkey has been reported to be a low-incidence
country for TB [2,3]. When extrapulmonary TB is taken into
consideration, 10–35% of the cases refer to spinal tuberculosis
(ST), also known as Pott disease [4,5].
Spondylodiscitis (SD) or vertebral osteomyelitis (VOM)
usually involves the inﬂammation or infection of the interver-
tebral disc and the adjacent vertebrae. This disease is most
commonly seen in patients older than 50 years, with a male
predominance; it leads to signiﬁcant morbidity [6–9]. The
aetiologic agents of VOM may be bacteria, fungi or parasites,
and their incidence varies in different geographical areas and
with underlying diseases [7,10]. When the infecting agent is
Mycobacterium tuberculosis complex, it is called ST [1]. In pre-
vious reports, delayed diagnosis and management are the major
factors determining unfavourable outcomes such as spinal cord
compression and deformities [7,11]. It may result in vertebral
collapse and severe destruction, along with skeletal deformities
and functional disability. In addition, compression of the spinal
cord and/or nerve roots may result in neurologic deﬁcits.
Involvement of paravertebral soft tissues is a common feature
of ST.inical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfecWe sought to describe clinical, laboratory, diagnostic and
therapeutic features, and clinical outcomes of ST in a large
series of patients.Materials and methodsStudy design and data collection
The Backbone studies are two consecutive retrospective
multinational/multicentre surveys. The Backbone-1 study
compared brucellar and tuberculous SD patients, and its results
will be published elsewhere. The Backbone-2 study, our focus
here, included 314 patients with ST diagnosed and treated in 35
different centres between January 2000 and September 2013.
The study period was the same in all of the centres involved in
the study. Data of the patients were retrieved from hospital
records and entered into a computer-based database designed
for this study. The patients were followed for at least 6 months
after termination of therapy. This study was approved ethically
by the institutional review board of Dr Lutﬁ Kirdar Education
and Research Hospital.
Inclusion criteria were as follows: patients with clinical and
radiologic evidence of inﬂammation of one or more vertebrae
and/or discitis plus microbiologic evidence and/or histopatho-
logic evidence (caseating granulomas) of TB on bone, with or
without paravertebral soft tissue specimen with or without
other specimen rather than SD, and/or clinical and radiologic
response to anti-TB therapy.
Microbiologic evidence included at least one of the following:
isolation of M. tuberculosis in blood, bone, bone marrow, deep
soft tissues and/or (paravertebral, epidural or psoas) abscess
specimens; positive microscopy for acid-fast bacilli from bone,
bone marrow, deep soft tissue and/or (paravertebral, epidural
or psoas) abscess or any sterile body tissue (Ziehl–Neelsentious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1008.e9–1008.e18
1008.e11 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMIstaining); positive rapid culture system results, such as BACTEC
460TB; or PCR for M. tuberculosis complex.
Imaging studies—magnetic resonance imaging (MRI),
computed tomography (CT) or scintigraphy—were performed
to deﬁne SD [12,13]. Radiologic criteria compatible with the
diagnosis of ST included the following: hypointense signal on
T1-weighted images; hyperintense signal on T2-weighted im-
ages; decreased height of intervertebral disc; osteolytic
appearance of vertebral end plates; epidural involvement; par-
aspinal abscess with a thin and smooth abscess wall or rim
enhancement; spread to three or more vertebral levels;
involvement of multiple vertebral bodies; and mostly thoracic
or lumbar spine involvement.
Exclusion criteria [6,14] included the following: age younger
than 18 years; positive Wright standard agglutination test result;
positive Brucella Coombs test result; enzyme-linked immuno-
sorbent assay (ELISA) positive for Brucella; isolation of Brucella
spp. from blood, bone, bone marrow, deep soft tissue and/or
abscess (paravertebral, epidural or psoas) culture; and growth
of pyogenic bacteria or fungi in the culture of the materials
obtained from blood, bone, bone marrow, deep soft tissue and/
or abscess material.
Deﬁnitions
VOM/SD was deﬁned as the infection of the intervertebral disc
and the adjacent vertebrae. Tuberculous SD/ST (TB) was
deﬁned as VOM caused byM. tuberculosis complex. Clinical cure
was deﬁned as resolution of all signs and symptoms of ST
without any sequelae. Unfavourable outcome (UO) was deﬁned
as death or survival with sequelae or disability as irreversible
neurologic or orthopaedic damage. We deﬁned sequela as any
morbid pathologic condition that is a consequence of ST, such
as persistent pain, abnormal anatomic spinal ﬁndings (e.g. Gib-
bus deformity, scoliosis) or functional limitation, persisting for
longer than 6 months after treatment. Neurologic deﬁcit was
deﬁned as compromise/loss of sensory and/or motor neuro-
logic function by compression of the spinal cord or nerve roots.
Gibbus deformity was deﬁned as a type of structural kyphosis of
any vertebral level resulting from wedge-shaped vertebral
bodies. Scoliosis was a form of deformity caused by curvature
of the spine in the coronal plane. Kyphosis was posterior
curvature of the thoracic spine beyond the normal physiologic
limit in the sagittal plane.
Microbiologic tests
Microbiologic diagnosis was established with direct and indirect
methods including the following.
Acid-fast bacilli. We tested for bacilli (e.g. Mycobacteria, Nocardia)
that did not decolorize with acid–alcohol.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectAcid-fast staining. Ziehl–Neelsen stain, Kinyoun stain or aur-
amine–rhodamine stain were used to detect acid-fast bacilli.
Culture. Culture was the reference standard for the diagnosis of
TB. However, 3–8 weeks were required for the growth of
Mycobacteria in solid culture media (Lowenstein-Jensen, Middle-
brook 7H11). Liquid broth cultures (Mycobacterial Growth
Indicator Tube (MGIT) system, Middle-brook 7H12) showed
organism growth in 1–3 weeks.
Nucleic acid ampliﬁcation tests. These automated molecular tests
included GeneXpert MTB/RIF real-time PCR assay (Cepheid,
Sunnyvale, CA), Ampliﬁed M. tuberculosis Direct Test (Gen-
Probe, San Diego, CA) and AMPLICOR M. tuberculosis Test
(Roche Diagnostic Systems, Basel, Switzerland). Their sensi-
tivity and speciﬁcity are nearly similar to those of culture.
Drug susceptibility tests. These tests included the agar proportion
method, GeneXpert MTB/RIF assay, INNO-LiPA Rif. TB kit
(Innogenetics, Zwijndrecht, Belgium) and Genotype
MTBDRplus assay (Hain Life-science, Nehren, Germany).
Tuberculin skin test (TST). Five tuberculin units of puriﬁed pro-
tein derivative in 0.1 mL solution was injected intradermally,
and the induration was measured 48–72 hours later. An
induration more than 10 mm diameter in immunocompetent
people corresponded to M. tuberculosis or latent TB infection.
The QuantiFERON-TB Gold In-Tube Test (QFT-GIT), a type of
interferon gamma release assay, was used to determine latent
or active TB.
Statistical analyses
SPSS 17.0 (IBM, Armonk, NY) was used for statistical analysis.
Categorical variables were presented as frequency and per-
centage, and continuous variables were presented as
mean ± standard deviation, and if not normally distributed as
median (range). Chi-square or Fisher’s exact test (two sided)
was used for categorical variables. Student’s t test or the Mann-
Whitney U test was used for continuous variables, as appro-
priate. All variables associated with UO on univariate analysis
with a p value of <0.2 were entered in a stepwise logistic
regression analyses. The logistic regression model was inter-
nally validated with bootstrap analysis.ResultsDemographic and clinical features
A total of 314 patients (163 (52%) men) with ST from 35
different centres in four countries (Turkey, Egypt, Albania and
Greece) were included. The mean age was 51 ± 18 years (rangeious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1008.e9–1008.e18
CMI Batirel et al. Course of spinal tuberculosis 1008.e1218–91 years). Fifty-two (17%) of the patients’ cohort and 21%
of the subgroup with UO had another site of TB involvement
(most commonly concomitant pulmonary TB). Comorbidities
of the patients included diabetes mellitus (n = 36, 12%), chronic
renal failure (n = 14, 5%), malignancy (n = 7, 2%), immuno-
suppression due to treatment with antineoplastic chemo-
therapy, glucocorticoids, TNF-alpha blockers (n = 7, 2%), and
other (e.g. hypertension, coronary artery disease, chronic
obstructive pulmonary disease, asthma, nephrolithiasis) (n = 60,
19%). Distribution of other sites of TB involvement is shown in
Table 1.
The median duration from initial symptoms to the time of
diagnosis was 78 days (range 2–1095 days). The majority of the
patients experienced back pain (83%), and more than half
experienced upper back pain (56%). The most common ﬁnding
was tenderness over the involved area. Other signs and
symptoms are listed in Table 1.
Laboratory ﬁndings
All of the patients were tested for anti-HIV by ELISA. None of the
patients were infected with HIV. TST positivity was 75%. Median
(range) erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) levels were 70 (4–159) mm/h and 30 (10–527)
mg/L, respectively. Only 28% (n = 88) of the patients had
leukocytosis (>10 000/mm3), while 2.5% had leucopenia
(<4000/mm3). Levels of other laboratory parameters were as
follows: median white blood cell count (range): 8811
(945–34 960)/mm3, median CRP (range): 30 (10–527) mg/L,
median ESR (range): 70 (4–159) mm/h, mean hemoglobin:
11.5 ± 1.8 g/dL, mean platelet count: 292 866 ± 112 376/mm3,
median alanine aminotransferase (range): 23 (3–215) IU/L, me-
dian aspartate aminotransferase (range): 24 (2–194) IU/L, me-
dian lactate dehydrogenase (range): 237 (48–912) IU/L, median
creatinine (range): 0.8 (0.2–9) mg/dL, mean serum protein:
7 ± 4.5 mg/dL, mean serum albumin: 3 ± 0.7 mg/dL.
Imaging data and level of vertebral involvement
Radiologic diagnosis was established by MRI in 92% (n = 289) of
the patients. CT scanning and scintigraphy were performed in
118 (38%) and 26 (8%) of the patients. The mean number of
involved vertebrae was 2.5 ± 1 vertebrae. Lumbar vertebrae
(56%) were the most commonly involved region of the spinal
column, followed by thoracic vertebrae (49%), but in the UO
group, thoracic vertebral (58%) and lumbar involvements (57%)
were similar. Although 51% of the patients (61% of the UO
group) had adjacent multiple (>1 vertebra) levels of vertebral
involvement, 8% had nonadjacent or noncontiguous involve-
ment of multiple (>1 vertebra) vertebral bodies. Imaging ﬁnd-
ings of the patients with ST are provided in Table 2.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfecMicrobiologic and histopathologic diagnosis
TST was performed in 210 patients (67%), with positive results
in 158 (75%). The yield of diagnostic tests is demonstrated in
Fig. 1. The aetiologic agent was isolated in 41% (75% from
paravertebral abscess material) of the patients with samples
that could be cultured, but an antimycobacterial susceptibility
test was performed in only 21% (n = 65) of the isolates. His-
topathologic examination (HPE) (most commonly of the para-
vertebral soft tissues (47%)) was performed in 200 patients
(64%); 74% were inconsistent with TB. HPE was inconclusive in
19% (n = 38) of patients.
Neurologic compromise/complications
Pretreatment assessment of neurologic function and spinal
stability revealed that the most common ﬁndings at baseline
were abscess formation (69%) (with the majority paravertebral
at 39%), neurologic deﬁcits (40%), spinal instability (21%) and
spinal deformity (16%). These ﬁndings were more commonly
seen in patients who ultimately had UO with abscess formation
in 74%, neurologic deﬁcits in 56%, spinal instability in 36% and
spinal deformity in 61% (p < 0.05). Complications that devel-
oped during the course of treatment were neurologic deﬁcits
(6%) and spinal deformities (4%). Data regarding complications
are presented in Table 3.
Therapeutic features
Medical treatment alone was implemented in 103 patients (33%).
A four-drug therapy including isoniazid (INH) + rifampin
(RMP) + pyrazinamide (PZA) + ethambutol (EMB) and a four-
drug regimen composed of INH + RMP + PZA + streptomycin
(STM) were administered to 261 patients (83%) and 22 patients
(7%) for the initial 2 months, respectively. Twenty-nine patients
(9%) received initial ﬁve-drug (INH + RMP + PZA + EMB + STM)
combination therapy. Antibiotic susceptibility testing was per-
formed only in ﬁve of the patients receiving the ﬁve-drug
regimen. After the initial four-drug regimen, most patients
continued to receive a two-drug regimen with RMP and INH for
a mean duration of 9 months. Adverse effects of anti-TB therapy
were noted in only 57 patients (18%), as follows: nausea/vom-
iting, 22 (38.6%); hepatotoxicity, 17 (29.8%); rash, 5 (8.8%);
leukopenia, 4 (7%); hearing problems, 3 (5.2%); fever, 2 (3.5%);
signiﬁcant hyperuricemia causing gouty arthritis or joint pain, 2
(3.5%); vertigo, 2 (3.5%); and blurred vision, 1 (1.8%). Adverse
effects were assumed to be related to INH and RMP (17%),
RMP (9%), PZA (7%), EMB (3%), STM (5%) and
INH + RMP + PZA + EMB (6%). In 13 patients (4%), desensiti-
zation to drugs had been performed before the reinitiation of
medical therapy. In 276 patients (88%), anti-TB therapy resulted
in expected favourable outcomes. Treatment was modiﬁed in 25tious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1008.e9–1008.e18
TABLE 1. Demographic characteristics, clinical and laboratory features, imaging ﬁndings and complications of 314 patients with
spinal TB
Characteristic Favourable outcome Unfavourable outcomea p
Total 230 84
Age (years) 50.7 ± 18 53.9 ± 18 0.06
Male sex 117 (51) 46 (55) 0.54
Other site of concomitant TB involvement 34 (15) 18 (21) 0.09
Pulmonary TB 13 (6) 10 (12)
Pleural TB 3 (1) 3 (7)
Mediastinal TB lymphadenitis 0 2 (2)
TB meningitis 11 (5) 2 (2)
Superﬁcial TB lymphadenitis 4 (1) 0
Gastrointestinal TB 1 (0.3) 0
Peripheral joint TB 1 (0.4) 1 (1)
Miliary TB 1 (0.3) 0
Clinical ﬁndings/constitutional symptoms
Fever 99 (43) 40 (48) 0.47
Fatigue 118 (51) 43 (51) 0.98
Loss of appetite 110 (48) 44 (52) 0.48
Sweating 112 (49) 40 (48) 0.87
Arthralgia 101 (44) 30 (36) 0.19
Lumbago/local tenderness 200 (87) 61 (73) 0.003
Back pain/local tenderness 127 (55) 49 (58) 0.62
Weight loss 98 (43) 34 (41) 0.79
Weight loss (kg) 8 ± 3 8 ± 3 0.37
Hepatomegaly (missing data in 9 patients) 30 (13) 11 (13) 0.96
Splenomegaly (missing data in 12 patients) 28 (12) 6 (7) 0.21
Imaging ﬁndingsb
Compatible with spondylodiscitis 215 (93) 83 (99) 0.06
Prevertebral abscess 25 (11) 12 (14) 0.40
Paravertebral abscess (missing data in 1 patient) 135 (59) 53 (63) 0.41
Epidural abscess (missing data in 1 patient) 35 (15) 19 (23) 0.11
Psoas abscess (missing data in 2 patients) 51 (22) 24 (29) 0.23
Radiculitis (missing data in 1 patient) 8 (3) 8 (10) 0.03
Neo-ossiﬁcation (missing data in 1 patient) 10 (4) 9 (11) 0.03
Anterior involvement (missing data in 6 patients) 75 (33) 39 (46) 0.02
Multiple vertebral involvement (missing data in 6 patients) 108 (47) 51 (61) 0.04
Loss of vertebral corpus height 101 (44) 50 (60) 0.01
Calciﬁcation (missing data in 18 patients) 29 (13) 7 (8) 0.26
Instability (missing data in 18 patients) 29 (13) 28 (33) <0.0001
Involved vertebrae
Cervical 14 (6) 1 (1) 0.07
Cervicothoracic 3 (1) 0
Thoracic 104 (45) 49 (58) 0.05
Thoracolumbar 24 (10) 16 (19) 0.85
Lumbar 127 (55) 48 (57) 0.86
Lumbosacral 18 (8) 6 (7) 0.40
Sacral 21 (9) 6 (7) 0.42
No. of involved vertebrae (missing data in 8 patients) 2 (1–8) 2 (1–6) 0.44
Multiple (>2 vertebrae) level involved (missing data in 7 patients) 72 (31) 34 (41) 0.15
Nonadjacent multiple-level involvement 14 (6) 12 (14) 0.04
Pretreatment complications
Neurologic deﬁcit 77 (33) 47 (56) <0.0001
Loss of sensation 34 (15) 24 (29)
Motor weakness 41 (18) 18 (21)
Paralysis 2 (0.8) 5 (6)
Spinal instability (missing data in 6 patients) 36 (16) 30 (36) <0.0001
Spinal deformity 0 51 (61) <0.0001
Abscesses 154 (67) 62 (74) 0.10
Paravertebral 77 (33) 46 (55)
Epidural 8 (3) 13 (15)
Psoas 46 (20) 14 (17)
>1 abscess 19 (8) 17 (20)
Peri- or posttreatment complications
Neurologic deﬁcit 0 20 (24) <0.0001
Spinal instability 0 5 (6) <0.0001
Spinal deformity 0 13 (16) <0.0001
Abscesses 3 (1) 4 (5) 0.07
Data are presented as n (%), mean ± standard deviation or median (range).
TB, tuberculosis.
aData were available as magnetic resonance imaging ﬁndings in 298 patients, as computed tomographic ﬁndings in 118 (38%) and as scintigraphic data in 26 (8%).
bDeﬁned as death or survival with any sequelae or disability despite therapy.
1008.e13 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMIpatients (8%) because of the adverse effects of the drugs (23.7%)
and inadequate therapy (2, 0.6%).
A diagnostic and/or therapeutic surgical intervention was
performed in 211 patients (67%); 37% received therapeutic
surgery in addition to medical treatment. CT/ultrasound-guided
percutaneous biopsy and/or abscess drainage (47%) was the
most common diagnostic and therapeutic interventionClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectperformed. Ten percent of the patients required more than one
surgical intervention.
Outcome analysis
In univariate analysis, the number of the patients with advanced
age (p 0.01), any malignant underlying disease (p 0.01), immu-
nosuppression (p 0.01), neurologic deﬁcit (p 0.004) and spinalious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1008.e9–1008.e18
CMI Batirel et al. Course of spinal tuberculosis 1008.e14deformity (p < 0.001) were signiﬁcantly higher in the UO
group. In multivariate analysis, advanced age, presence of
neurologic deﬁcit and spinal deformity were the independent
predictors of a UO (Table 4). Clinical cure was achieved in 230
patients (73.2%). Mortality occurred in 7 patients (2%); 77
(25%) developed any sequelae during or after treatment. The
rates of posttreatment sequelae were as follows: 11% kyphosis,
6% Gibbus deformity, 5% scoliosis, 5% paraparesis, 5% para-
plegia and 4% loss of sensation.DiscussionIn previously published Turkish studies on VOM, nearly one-
third of the patients had ST [10,15,16]. In a large case series
from Spain including 219 patients with VOM, ST constituted
approximately one-ﬁfth of the patients [5]. In the present study,
the mean age of the patients, slightly over 50, was inconsistent
with the previously published relevant literature in which most
patients were younger than 40 [7,17]. Male subjects were
slightly more predominant in our series, similar to the data
reported in a recently published update on VOM [7]. Because
back pain related to various causes is a common complaint in
many patients, patients may not be referred to a hospital or
seek medical care until symptoms get worse or the disease
becomes progressive. Moreover, despite advanced diagnostic
methods, diagnosis of ST is usually delayed: the median duration
of symptoms before diagnosis has been reported to be between
2.5 and 6 months [5,7,15,18,19]. Median diagnostic delay in this
study was 2.5 months, which was similar to the previous
studies. In our study, more patients (7%) had concomitant
active pulmonary TB compared to the previous largest case
series report (2.7%) [17]. However, this is in contrast to
another study from Turkey that reported disseminated TB in
19% of the patients with ST [10]. Less than half of the patients
presented with fever in our series. Fever is a less common
feature in ST, detected in only one-third of patients in other
studies [5,7,18]. It should be taken into consideration that
absence of fever in elderly patients with VOM may easily lead to
misdiagnosis [19]. Constitutional symptoms were also present
in nearly half of the patients. Lumbago and upper back pain
were the most common presenting symptoms, similar to the
ﬁndings reported by a majority of previous case series
[13,18,20]. In contrast, a meta-analysis of the Turkish literature
reviewing a large ST case series with a long follow-up period of
12 years by neurosurgeons and orthopedic surgeons docu-
mented that the most common presenting symptom was leg
weakness, followed by Gibbus deformity. Only one-ﬁfth of
patients complained of pain initially [17]. However, in the
present study, it was the other way round: leg weaknessClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecoccurred in only one-ﬁfth of the patients, while pain was
documented more frequently. The most probable reason for
this discordance is referral bias in the meta-analysis study, as all
the patients in that study were being followed by surgeons
because they had neurologic deﬁcits.
Rate of TST reactivity was 75% in this study. In a study on
VOM reported from Turkey including 63 patients with ST, the
sensitivity, speciﬁcity, positive predictive value and negative
predictive value of TST were 66%, 97%, 89% and 88%,
respectively [15]. TST and interferon gamma release assay tests
are used in the diagnosis of latent TB infection, and their pos-
itive results do not conﬁrm a diagnosis for active TB. Leukocyte
counts have usually been reported to be in the normal range in
ST [13]. In the present study, less than one-third of the patients
had leukocytosis, while only 2.5% had leukopenia. However,
ESR and CRP levels were usually elevated, similar to previous
case series [21].
Plain radiographs play a role in diagnosis despite their low
speciﬁcity—they are able to diagnose only half of the cases
accurately [7,8,13]. MRI and CT are the most frequently
preferred methods for diagnostic imaging [6,13,22]. CT is
commonly used as a means of guidance for biopsy [7]. MRI in
particular has a high sensitivity and speciﬁcity for early diagnosis
of ST and is superior to other radiologic methods in revealing
the extent of the disease and soft tissue involvement [6,7,13].
Therefore, radiologic diagnosis was established by MRI in the
majority (92%) of our patients who had imaging ﬁndings
compatible with ST in 95% of the cases [5]. However, spon-
taneous fusion of the vertebrae requires 12–24 months, and
follow-up MRI may show radiologic progression despite clinical
improvement of the patient [7]. Lower thoracic and upper
lumbar vertebrae with soft tissue abscesses were reported to
be involved in the majority of the patients with ST [5,7,15]. In
this study, lumbar vertebrae were the most commonly involved
site, followed by thoracic spine. However, in patients with UO,
the disease affected thoracic vertebrae and lumbar vertebrae
equivalently. Spinal deformity or instability may have been
present at the time of diagnosis of ST [5]. Our results are
consistent with those of previous studies, as more than half of
our patients with UO had spinal deformity at the time of
diagnosis. Spinal instability was seen in one-third of our patients
with UO. Multiple segment (>1 vertebra) involvement has been
reported to be a feature of ST [7]. In agreement with these
updated data, in one-third of our patients, multiple (>1)
vertebrae were affected, in contrast to some other studies
(2.4–3%) [5,10]. The authors of those reports may have
referred to nonadjacent or noncontiguous involvement of
multiple vertebral bodies as multiple segment involvement
because the deﬁnition of “multiple” is not clear in those studies.
Paraspinal, epidural and/or paravertebral abscesses weretious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1008.e9–1008.e18
TABLE 2. Results of microbiologic and histopathologic
diagnostic tests for tuberculous spondylodiscitis
Characteristic n (%)
Positive culture 110/271 (41)
Culture specimen
Blood culture 2 (0.6)
Bone biopsy culture 12 (4)
Bone marrow culture 1 (0.3)
Deep soft tissue culture 16 (5.1)
Abscess material culture 78 (25)
Paravertebral abscess 54 (17)
Epidural abscess 5 (1.6)
Psoas abscess 21 (6.7)
Lymph node culture 1 (0.3)
Identiﬁcation of Mycobacteria
Mycobacterium tuberculosis complex 59 (54)
M. tuberculosis 49 (45)
Antimicrobial susceptibility test performed 3 (1)
HPE performed 200
Compatible with TB 147 (74)
Nonspeciﬁc ﬁndings 38 (19)
Insufﬁcient material 15 (7)
Site of HPE
Bone 52 (26)
Paravertebral soft tissue 94 (47)
Bone and paravertebral soft tissue 15 (8)
Other foci 36 (18)
Vertebral level material for HPE obtained
Cervical 7 (4)
Thoracic 82 (41)
Lumbar 76 (38)
Sacral 1 (0.5)
HPE, histopathologic examination; TB, tuberculosis.
1008.e15 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMIreported in the majority of our patients with ST, with rates
similar to those of previous studies [5,10,18,21,23]. In contrast
to previous case series [17], more of our patients (8%) had
nonadjacent or noncontiguous involvement of multiple verte-
bral bodies.92
110
52
14
1
179
161
36
3
0
20
40
60
80
100
120
140
160
180
200
220
240
260
280
Number of paƟents
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectNeurologic compromise may occur as a result of cord
compression by a large abscess, particularly in cases with
delayed diagnosis [7,11]. Neurologic symptoms and/or spinal
cord compression have been reported to be between 16% and
69% in various studies [5,7,10,17,18,21,23]. In our series, pre-
treatment presence of neurologic deﬁcit was present in more
than half of the patients with UO. Kyphosis and Gibbus
deformity have been reported to be common spinal deformities
in ST [7]. In the present study, both types of deformities were
the most common deformities detected in patients with UO.
Because they may require surgical intervention, close moni-
toring of the neurologic status of the patient is necessary [22].
For the deﬁnitive diagnosis of ST, microbiologic and/or his-
topathologic analyses are necessary [6]. Previous publications
indicate that most surgeons and radiologists rely on microbio-
logic diagnosis. However, other physicians, including infectious
diseases specialists and pathologists, are aware that these
techniques may fail to diagnose ST [13]. Histopathologic diag-
nosis (64%) outweighed microbiologic diagnosis (41%) in our
case series. Sensitivity of cultures to detect the causative agent
has been reported to be 80% [24]. Negative microbiologic re-
sults should not exclude the diagnosis [13]. Nevertheless,
isolation of Mycobacteria is crucial to proceed to susceptibility
tests [24]. Percutaneous biopsy should be performed in any
patient with a clinical picture suggestive of VOM before initia-
tion of therapy [18]. Because it is sometimes difﬁcult to
convince patients to undergo a biopsy, and because47
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FIG. 1. Yield of different diagnostic
procedures. ARB, acid-fast bacteria;
PCR, polymerase chain reaction; HPE,
histopathologic examination.
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TABLE 3. Treatment and outcome of 314 patients with spinal
tuberculosis
Treatment Value
Treatment
INH, RIF, PRZ, EMB 261 (83)
INH, RIF, PRZ, STM 22 (7)
INH, RIF, PRZ, EMB, STM 29 (9)
Corticosteroid therapy 13 (4)
Missing data 2 (1)
Duration of therapy (months) 11.6 ± 2.5
Surgical intervention 211 (67)
Percutaneous biopsy with or without abscess drainage 100 (47)
Open abscess drainage 34 (16)
Transpedicular stabilization and fusion 23 (11)
Multiple surgical interventions 22 (10)
Laminectomy 13 (6)
Drainage and intermittent irrigation 7 (3)
Corpectomy and stabilization 1 (0.4)
Diskectomy 1 (0.4)
Reason for surgical intervention
Diagnostic 49 (23)
Diagnostic and therapeutic 68 (32)
Therapeutic 78 (37)
Any surgical complication 2 (0.9)
Reasons for surgical intervention
Pain 57 (27)
Neurologic deﬁcit 24 (11)
Not documented 130 (62)
Response to treatment
Clinical (fever, pain relief) cure 230 (73)
Laboratory improvement 242 (77)
CRP normalization 246 (78)
Time to CRP normalization (days) 16 (70, 7)
ESR normalization 198 (63)
Time to ESR normalization 28 (120, 30)
Follow-up imaging results
Cure 48 (15)
Radiologic improvement 137 (44)
Worsening of radiologic ﬁndings 13 (4)
Unfavourable outcomes 84 (27)
Mortality 7 (2)
Posttreatment sequelaea 77 (25)
Kyphosis 35 (11)
Gibbus deformity 18 (6)
Motor weakness 17 (5)
Paraplegia 17 (5)
Scoliosis 15 (5)
Loss of sensation 12 (4)
Kyphoscoliosis 3 (1)
Vertebral compression fracture 2 (0.6)
Persistent pain 2 (0.6)
Urinary retention 1 (0.3)
Polyneuropathy 1 (0.3)
Data are presented as n (%), mean ± standard deviation or median (interquartile
range).
CRP, C-reactive protein; EMB, ethambutol; ESR, erythrocyte sedimentation rate;
INH, isoniazid; PRZ, pyrazinamide; RIF, rifampin; STM, streptomycin.
aNumber of diagnoses, not patients.
CMI Batirel et al. Course of spinal tuberculosis 1008.e16experienced radiodiagnostic specialists are needed to perform
CT/ultrasound-guided biopsy, HPE could only be done in 64%
of our cases, three-fourths of the ﬁndings of which were
compatible with TB. In another study, invasive procedures (e.g.
bone biopsy) for diagnosis were performed in three-fourths of
patients with ST [21]. In 66–90% of patients who underwent
biopsy, the diagnosis of ST was established microbiologically
and/or histopathologically [10,24]. Culture results have been
reported to reveal the causative pathogen in up to half of
percutaneous biopsies and in more than half of open biopsies.
After histologic ﬁndings were evaluated together with micro-
biologic results, the diagnostic yield of percutaneous biopsies
has been known to increase [18,23]. Molecular methods likeClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfecPCR may help in diagnosis of culture-negative cases and may
prevent misdiagnosing ST as pyogenic VOM. Particularly, PCR
offers an alternative means of diagnosis in patients who
received antibiotics previously and those who were infected
with fastidious-growing microorganisms [25]. PCR may also
have false-negative or false-positive results as a result of
contamination [13,25].
Multidrug regimens starting with four drugs and continuing
with two more are recommended for treatment of TB. In the
past, longer courses (12–18 months) of anti-TB therapy had
been recommended for ST. However, later it was demonstrated
that 6 to 9months of regimens including RMPwere as effective as
longer-duration regimens [26]. In the case of advanced disease
with complications, or if RMP cannot be included in the regimen
for whatever reason, treatment duration may have to be
lengthened [27]. In the present study, mean duration of therapy
was nearly 1 year (11.6 months). One-third of our patients
received medical treatment alone. Conservative medical treat-
ment in patients without neurologic symptoms or spinal de-
formities resulted in clinically successful therapeutic responses in
95% of the patients [23]. Surgical intervention is necessary to
obtain specimens for diagnostic purposes when percutaneous
aspiration fails to disclose the aetiology, or when neurologic
deﬁcits, spinal instability, kyphosis of >40 degrees and cold ab-
scess are present [11,28,29]. The rate of necessity for surgical
intervention is higher in ST compared to VOM caused by other
pathogens [5,21,22]. The need for urgent decompression is the
main reason for emergency surgery in patients with neurologic
symptoms. In a meta-analysis including surgical patients with ST,
the causes of surgery were documented as follows: spinal
deformity in 59%, neurologic deﬁcits in 38%, intractable pain in
3% and abscess enlargement unresponsive to medications in 3%
[17]. In our study, 67% of patients required surgical intervention,
and 67% of themwere for therapeutic purposes. In other studies
that included fewer patients with neurologic deﬁcits or defor-
mity, the rate of surgery was accordingly low [10].
Mortality occurred in 7 patients (2%); the mortality rate was
the same as that reported in a meta-analysis from Turkey [17].
Seventy-seven patients (25%) developed any sequelae, such as
kyphosis, Gibbus deformity, scoliosis, paraparesis, paraplegia
and loss of sensation, in descending order. Patients with
advanced age, malignant underlying diseases, immunosuppres-
sion, neurologic deﬁcit and spinal deformity had more UO.
Advanced age, presence of neurologic deﬁcit and spinal defor-
mity were independent predictors of a UO and also accounted
for the indications for surgery [22]. Although the rates of
neurologic deﬁcits before therapy and surgical intervention in
the present study were similar to those reported by Colme-
nero et al. [18], the number of patients with severe functional
sequela was much lower (25%) than the number of patients intious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1008.e9–1008.e18
TABLE 4. Comparison characteristics of patient with spinal tuberculosis for favourable and unfavourable outcomes
Characteristic
Univariate analysis Multivariate analysis
Favourable outcome (n [ 230) Unfavourable outcome (n [ 84) p Adjusted OR (95% CI) p
Age (years) 49 ± 18 56 ± 16 0.013 1.02 (1.0–1.04) 0.030
Female sex 122 (48.2) 29 (47.5) 0.92 — —
Diabetes mellitus 29 (11.5) 7 (11.5) 1.00 — —
Chronic renal disease 11 (4.3) 3 (4.9) 0.85 — —
Malignant underlying disease 3 (1.2) 4 (6.6) 0.01 3.09 (0.51–18.65) 0.22
Immunosuppression 3 (1.2) 4 (6.6) 0.01 3.52 (0.68–18.37) 0.14
Neurologic deﬁcit 79 (31.2) 31 (50.8) 0.004 1.93 (1.03–3.61) 0.041
Spinal instability 51 (20.2) 15 (24.6) 0.45 — —
Abscess formation 169 (66.8) 45 (73.8) 0.29 — —
Spinal deformity 21 (8.3) 23 (37.7) <0.001 5.42 (2.65–11.09) <0.0001
Duration of symptoms before diagnosis (days) 149 ± 187 (n = 250) 193 ± 227 (n = 61) 0.11 1.00 (1.0–1.0) 0.086
Data are presented as mean ± standard deviation or n (%).
CI, conﬁdence interval; OR, odds ratio.
1008.e17 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMIthat study (39%). Among patients who were treated surgically
in addition to medical anti-TB therapy, only 9% were reported
to have experienced deterioration after treatment [17]. All the
others improved or remained stable.
There were some limitations of our study. Because all the
contributors of this study are infectious diseases clinicians, we
could not assess the details of surgical procedures and their
outcomes. Furthermore, because the study was retrospective
in nature, we were also limited by the data available in the
medical records.
In conclusion, ST results in a signiﬁcant rate of morbidity as a
result of its insidious course and delayed diagnosis. Patients with
complications already present before the initiation of treatment
were more likely to develop neurologic sequelae. Advanced
age, presence of any neurologic deﬁcit and spinal deformity
were predictors of UO in this study. ST should be considered in
the differential diagnosis of patients with VOM, especially in TB-
endemic regions. Early establishment of deﬁnitive aetiologic
diagnosis and appropriate treatment are of paramount impor-
tance to prevent development of sequelae.Transparency declarationAll authors report no conﬂicts of interest relevant to this
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